Mapp Biopharmaceutical

Mapp Biopharmaceutical is a US company based in San Diego that is active in the field of biotechnology .

Companies

The company was founded in 2003 by Kevin J. Whaley and Larry Zeitlin and had nine employees in August 2014. The company is privately owned but funded solely by funds and orders from the United States government.

Research fields

According to the company, it deals with the development of drugs for the prevention and treatment of infectious diseases, for which there is a global demand. As soon as the developed drugs are in the clinical test stage, the patents will be passed on to the commercial partner LeafBio .

In the summer of 2014, a drug ( ZMapp ) that had been developed and had not yet been approved was successfully used on two Americans in the course of the 2014 Ebola fever epidemic in West Africa .

Individual evidence

↑ Andrew Pollack, "Ebola Therapy From an Obscure Biotech Firm Is Hurried Along" NYT August 6, 2014, viewed August 6, 2014
↑ Experimental drug likely saved Ebola patients. Retrieved August 5, 2014 .
↑ Xiangguo Qiu, Gary Wong u. a .: Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. In: Nature. 2014, doi : 10.1038 / nature13777 .

Web links

Web site Mapp Biopharmaceutical (English)

[1] Andrew Pollack, "Ebola Therapy From an Obscure Biotech Firm Is Hurried Along" NYT August 6, 2014, viewed August 6, 2014

[2] Experimental drug likely saved Ebola patients. Retrieved August 5, 2014 .

[3] Xiangguo Qiu, Gary Wong u. a .: Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. In: Nature. 2014, doi : 10.1038 / nature13777 .